ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VCRE / earnings
VRDN (45) MBX (40) NRIX (46) PGEN (33) ⌘ Pro Terminal →

Vicore Pharma Holding AB (VCRE) Next Earnings Date & Expected ±12.5% Move

$9.59 -2.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.53

Vicore Pharma Holding AB (VCRE) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.76B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VCRE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VCRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Vicore Pharma Holding AB (NASDAQ: VCRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $9.59 (-2.14% 1D, market cap $2.76B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, VCRE ranks #272 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VCRE compare to VRDN and MBX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VCRE carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VRDN (Viridian Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.79B) and MBX (MBX Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -26.4%, cap $2.69B). Among the 5-stock peer group, VCRE leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VCRE?
▼

For Vicore Pharma Holding AB (VCRE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #272 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.53 (-0.58%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510049
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk D+
Cash (12)Whales (6)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
$19 Bull$9 Base$7 Bear
📬 FREE VCRE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCRE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY VCRE SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 1.9% FCF Margin ($77.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$8.95+0.6% Next Q
Q2 (-2Q)
44
Grade D$9.00+3.9% Next Q
Q3 (-1Q)
46
Grade D$9.35+2.6% Next Q
Current
49
Grade D$9.59-5.4% Hist 90D α
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VCRE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VCRE currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.07) and Max Pain ($10.07) forces dealer call-delta covering toward $18.69.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VCRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VCRE Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.20 Expected Swing
$8.39 (-12.5%)Spot $9.59$10.79 (+12.5%)
MODEL EARNINGS SETUP GAUGE

VCRE Quantitative Pre-Earnings Setup: 49/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (49/100)Model Risk Weight (51/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VCRE)

  • ✓Walkthrough of VCRE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VCRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.98%▼ DESCENDING CHANNEL
2026-11-03O $10.20H $10.20L $9.59C $9.59VOL 11.9K
RES: $11.14SUP: $5.91SMA50: $10.07SMA200: $10.98
$18.49$15.62$12.74$9.86$6.99RES $11.14SUP $5.91$9.592026-07-062026-08-042026-09-022026-10-022026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VCRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VCRE Butterfly Map → + Track VCRE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VCRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VCRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VCRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCRE)

Health Care Rank #272 of 1015 ⚔️ VRDN vs VCRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VCRE vs. VRDN, MBX, NRIX, PGEN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Vicore Pharma Holding AB (VCRE) ranks #272 by composite RQD confidence (49/100, grade D) and #213 by equity capitalization ($2.76B). Within this direct 5-issuer industry benchmark cohort, VCRE leads on earnings valuation at N/A trailing P/E, while MBX leads on capital efficiency and profitability with -26.4% ROIC and — gross margin. VCRE currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VCRE ACTIVE
Vicore Pharma Holding AB
D 49/100 — — — -2.14% $2.76B Benchmark Subject
VRDN
Viridian Therapeutics Inc.
D 45/100 — — -35.0% +2.55% $2.79B /vrdn-vs-vcre →
MBX
MBX Biosciences Inc.
D- 40/100 — — -26.4% -2.63% $2.69B /mbx-vs-vcre →
NRIX
Nurix Therapeutics Inc.
D 46/100 — — -35.0% -4.10% $2.93B /nrix-vs-vcre →
PGEN
Precigen Inc.
E 33/100 — — -35.0% -25.94% $2.48B /pgen-vs-vcre →

2. VCRE Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Vicore Pharma Holding AB (VCRE) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.76B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. VCRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VCRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Vicore Pharma Holding AB (NASDAQ: VCRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $9.59 (-2.14% 1D, market cap $2.76B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, VCRE ranks #272 in composite RQD confidence.

How does VCRE compare to VRDN and MBX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VCRE carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VRDN (Viridian Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.79B) and MBX (MBX Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -26.4%, cap $2.69B). Among the 5-stock peer group, VCRE leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VCRE?

For Vicore Pharma Holding AB (VCRE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #272 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VCRE trading relative to its 50-day, 200-day, and 52-week technical levels?

VCRE last traded at $9.59 (-2.14% on volume of 7,210 shares), positioning the stock -4.77% below its 50-day simple moving average ($10.07) and -12.66% below its 200-day simple moving average ($10.98). Across its 52-week range of $7.88 to $17.80, VCRE sits at the 17.2% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.39 to $10.79).

Direct Sub-Reports: VCRE RQD Cockpit VCRE 12M Forecast VCRE Earnings & Move VCRE Dividends & DRIP VCRE Insiders & 13F VCRE Whale Options VCRE Profit Sankey VCRE News & Why
ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ SEC XBRL & RQD VERIFIED

VCRE — Vicore Pharma Holding AB: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Vicore Pharma Holding AB (VCRE) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.59 (-2.14% 1D, market capitalization $2.76B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vicore Pharma Holding AB (VCRE) is listed on NASDAQ and classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. The profile identifies it as a NASDAQ-listed issuer with a market capitalization of $2.9B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 49/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $7.88 – $17.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be identified from source data. Sector context is limited to the Health Care classification and the Biotechnology: Pharmaceutical Preparations industry label. No sector correlation data or second-order bottlenecks are available in source data.

  • Key Question #1: Can VCRE sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $17.80 52-week high?
  • Key Question #3: How sensitive is VCRE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VCRE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vicore Pharma Holding AB (VCRE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VCRE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VCRE Bull vs. Bear Conversation Board — What's Your Call at $9.59?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VCRE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VCRE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $12.84 (+31.0%)
📌 Pinned Debate

Balance-sheet forensics are the strongest pillar, with an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of

Don't sleep on VCRE's setup in Health Care. Balance-sheet forensics are the strongest pillar, with an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5, and the price of 10.2 sits well above the 52-week low of $7.88.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (49/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — VCRE's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $7.64 (-22.0%)
Spot @ $9.80

The cash-generation, institutional, and insider pillars are weak, with ROIC and FCF yield both at 0% and an RQD score of 51 carrying a

I respect the product at Vicore Pharma Holding AB, but the stock at $9.80 is a different story. The cash-generation, institutional, and insider pillars are weak, with ROIC and FCF yield both at 0% and an RQD score of 51 carrying a D grade and a Sell verdict.. FCF yield is 0.0% and RQD sits at 49/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE